Martin Shkreli

From WikiMD's WELLNESSPEDIA

Martin Shkreli (born March 17, 1983) is an American businessman, former hedge fund manager, and convicted felon. He is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare; the co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin; and the founder and former CEO of Turing Pharmaceuticals.

Early Life and Education[edit]

Shkreli was born in Brooklyn, New York, to Albanian and Croatian immigrants who worked as janitors. He attended Hunter College High School and later graduated from Baruch College with a bachelor's degree in business administration.

Career[edit]

Shkreli began his career in finance as an intern for Cramer, Berkowitz and Company when he was 17. He later co-founded hedge fund Elea Capital in 2006, which was closed after a lawsuit from Lehman Brothers in 2007. In 2009, Shkreli founded MSMB Capital Management, an investment firm that focused on healthcare.

In 2011, Shkreli started Retrophin, a biotechnology firm, and served as its CEO until 2014. He then founded Turing Pharmaceuticals in 2015, where he became infamous for raising the price of the life-saving drug Daraprim from $13.50 to $750 per pill overnight.

Legal Issues[edit]

In 2015, Shkreli was arrested by the Federal Bureau of Investigation (FBI) on charges of securities fraud. He was convicted in 2017 on two counts of securities fraud and one count of conspiring to commit securities fraud. He was sentenced to seven years in federal prison and ordered to forfeit $7.4 million.

Public Perception[edit]

Shkreli's actions at Turing Pharmaceuticals, particularly the price hike of Daraprim, led to widespread criticism and made him a symbol of corporate greed in the pharmaceutical industry. He has been referred to in the media as "the most hated man in America" and "Pharma Bro".

See Also[edit]

References[edit]


External Links[edit]

Stub icon

This article about a United States businessperson is a stub. You can help WikiMD by expanding the page.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


  • Martin Shkreli 2016
    Martin Shkreli 2016

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Martin_Shkreli&oldid=6348133"